Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

AdaptHealth (AHCO) EBIAT (2018 - 2026)

AdaptHealth has reported EBIAT over the past 8 years, most recently at -$106.3 million for Q4 2025.

  • For Q4 2025, EBIAT fell 306.78% year-over-year to -$106.3 million; the TTM value through Dec 2025 reached -$72.0 million, down 176.89%, while the annual FY2025 figure was -$70.8 million, 174.69% down from the prior year.
  • EBIAT for Q4 2025 was -$106.3 million at AdaptHealth, down from $24.5 million in the prior quarter.
  • Over five years, EBIAT peaked at $80.1 million in Q2 2021 and troughed at -$452.9 million in Q3 2023.
  • A 5-year average of -$20.9 million and a median of $16.0 million in 2022 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: skyrocketed 1259.53% in 2022 and later crashed 20732.63% in 2023.
  • Year by year, EBIAT stood at $24.9 million in 2021, then plummeted by 95.07% to $1.2 million in 2022, then crashed by 20732.63% to -$253.6 million in 2023, then skyrocketed by 120.27% to $51.4 million in 2024, then tumbled by 306.78% to -$106.3 million in 2025.
  • Business Quant data shows EBIAT for AHCO at -$106.3 million in Q4 2025, $24.5 million in Q3 2025, and $15.8 million in Q2 2025.